Navigation Links
Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials

CHICAGO, March 14, 2011 /PRNewswire/ -- Argentum Medical, LLC today issued a response to the recent decision in their patent infringement litigation versus Noble Biomaterials, Inc.

"The most important thing to know is the trial has no impact on our patents and it is business as usual for Argentum," said Gregg Silver, Chairman and CEO of Argentum Medical, LLC. "The case concerned non-patent issues and is currently being appealed. We are confident that our appeal will be successful."

Argentum Medical is an industry leader in antimicrobial silver dressings. The company manufactures more than 60 different combinations and sizes of Silverlon® products, and has developed 14 unique categories of wound, burn and post-surgical dressings. Argentum has sold more than three million dressings to more than 2,000 customers, including the Mayo Clinic, Johns Hopkins University, University of Michigan and the Department of Defense.

This month marks Argentum Medical's 10th anniversary. The company has experienced record sales in 2010, with the Silverlon Surgical Wound Pad and Island Dressings achieving domestic sales growth of more than 300% in the second half of the year.

Silver adds, "The litigation will not affect our customers. We will continue to provide our customers with Silverlon® and our other leading products. We are a financially strong company, and service to our customers will not be affected by any expenses resulting from this lawsuit."

Argentum prides itself on groundbreaking innovation, and has particular success with its Silverlon® Negative Pressure Dressing (NPD), which was named Innovative Product of the Year by Frost and Sullivan in 2006. NPD continues to be one of the company's fastest growing categories today. It was the first antimicrobial silver dressing designed to be utilized with negative pressure wound therapy.

About Argentum Medical

Headquartered in Chicago, Illinois, Argentum Medical is a leader in antimicrobial silver dressings. In early 2001, Argentum Medical was formed to commercialize patented and patent pending silver nylon technology. With the success of its burn products, the company diversified into other areas of wound care. Today, Argentum holds over 12 patents and is the only silver wound care company to manufacture over 60 different combinations and sizes for all aspects of acute and chronic patient care. For more information, visit

SOURCE Argentum Medical, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
2. WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
3. Sensus Healthcare Announces the Formation of a Medical Advisory Board
4. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
5. Aethlon Medical to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference
6. Cantel Medical Acquires the Sterilization Monitoring Business of ConFirm Monitoring Systems, Inc.
7. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
8. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
9. Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions
10. Californias Biomedical Industry is Poised for Growth Despite Increasing Global Competition, According to the 2011 California Biomedical Industry Report
11. Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):